Abstract
Complex molecular and cellular mechanisms are involved in the pathway of liver fibrosis. Activation and transformation of hepatic stellate cells (HSCs) are considered the two main reasons for the cause and development of liver fibrosis. The peroxisome proliferator-activated receptors (PPARs) belonging to the family of ligand-activated transcription factors play a key role in liver homeostasis, regulating adipogenesis and inhibiting fibrogenesis in HSCs. Normal transcriptional function of PPARs contributes to maintain HSCs in quiescent phase. A reduced expression of PPARs in HSCs greatly induces a progression of liver fibrosis and an increased production of collagen. Here, we discuss role and function of PPARs and we take into consideration molecular factors able to reduce PPARs activity in HSCs. Finally, although further validations are needed, we illustrate novel strategies available from in vitro and animal studies on how some PPARs-agonists have been proved effective as antifibrotic substances in liver disease.
Keywords: Cytokines, genes, HSCs, ligands, liver fibrosis, microcirculation, PPARs, antifbrotic therapy, transcription factors.
Current Medicinal Chemistry
Title:Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Volume: 20 Issue: 27
Author(s): E. M. Zardi, L. Navarini, G. Sambataro, P. Piccinni, F. M. Sambataro, C. Spina and A. Dobrina
Affiliation:
Keywords: Cytokines, genes, HSCs, ligands, liver fibrosis, microcirculation, PPARs, antifbrotic therapy, transcription factors.
Abstract: Complex molecular and cellular mechanisms are involved in the pathway of liver fibrosis. Activation and transformation of hepatic stellate cells (HSCs) are considered the two main reasons for the cause and development of liver fibrosis. The peroxisome proliferator-activated receptors (PPARs) belonging to the family of ligand-activated transcription factors play a key role in liver homeostasis, regulating adipogenesis and inhibiting fibrogenesis in HSCs. Normal transcriptional function of PPARs contributes to maintain HSCs in quiescent phase. A reduced expression of PPARs in HSCs greatly induces a progression of liver fibrosis and an increased production of collagen. Here, we discuss role and function of PPARs and we take into consideration molecular factors able to reduce PPARs activity in HSCs. Finally, although further validations are needed, we illustrate novel strategies available from in vitro and animal studies on how some PPARs-agonists have been proved effective as antifibrotic substances in liver disease.
Export Options
About this article
Cite this article as:
Zardi M. E., Navarini L., Sambataro G., Piccinni P., Sambataro M. F., Spina C. and Dobrina A., Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment, Current Medicinal Chemistry 2013; 20 (27) . https://dx.doi.org/10.2174/09298673113209990136
DOI https://dx.doi.org/10.2174/09298673113209990136 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
EDITORIAL (Thematic Issue: Preeclampsia and Modern Approaches to Diagnosis and Therapy)
Current Women`s Health Reviews Adenosine Myocardial Perfusion Imaging
Current Medical Imaging Beta-Blockers in the Management of Coronary Artery Disease: Are we on the Verge of a New Paradigm Shift?
Recent Patents on Cardiovascular Drug Discovery Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy
Current Drug Targets Free Radical Scanvenging and Antioxidant Effects of Some Anthraquinone Derivatives
Medicinal Chemistry Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Nutritional Status and Lipid Profile in HIV-Infected Adults
Endocrine, Metabolic & Immune Disorders - Drug Targets Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension
Current Hypertension Reviews Gene Therapy to Improve High-Density Lipoprotein Metabolism and Function
Current Pharmaceutical Design Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Chronotherapeutic Drug Delivery from Indomethacin Compression Coated Tablets for Early Morning Pain Associated Rheumatoid Arthritis
Current Drug Delivery Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Stem Cell Therapy in Heart Diseases: A Review of Selected New Perspectives,Practical Considerations and Clinical Applications
Current Cardiology Reviews Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Current Drug Targets Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Current Pharmaceutical Design PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations
Recent Advances in Drug Delivery and Formulation